Lantheus Sued by Novartis for Patent Infringement on Lutathera
Lantheus was sued by Novartis entities for patent infringement in response to the company’s filing of a Abbreviated New Drug Application for a generic version of lutathera.
Company believes it is the “first applicant” to have filed a substantially complete ANDA containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act
Company believes it is eligible for 180 days of generic marketing exclusivity in the US
Novartis has filed a lawsuit for patent infringement in the District Court for the District of Delaware
TLX Price at posting:
$11.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)